The National Center for Health Research is criticizing FDA for having fewer meetings with patients and public health advocates during the biosimilar user fee negotiations than during other use fee negotiations, and said this lack of engagement makes it difficult for the group to judge whether the new user fee agreement is adequate. NCHR President Diana Zuckerman also told Inside Health Policy that safety concerns are “getting the short end of the stick” in biosimilar user fee negotiations, due...